Unravelling the Mystery of Long COVID: HIQA Reviews Potential Interventions

By HEOR Staff Writer

July 31, 2023

HIQA continues to lead the charge in understanding and managing Long COVID. Their latest systematic review explores potential interventions aimed at improving the varied and often debilitating symptoms of this complex condition. While no definitive treatments have been identified yet, their research continue.

The review included 57 randomised controlled trials of interventions for adults with Long COVID symptoms, typically in people with less than a year’s duration and no pre-existing chronic illnesses. The studies varied in intervention type and were generally short-term, with small sample sizes and not enough focus on specific subpopulations like older adults or those with chronic conditions. There was also insufficient examination of intervention safety. The interventions proposed in this review for Long COVID symptoms lack sufficient evidence for their effectiveness. Personalised exercise and physiotherapy involving breathing exercises may have short-term benefits, but their long-term effects were not assessed. More research is needed to investigate the effectiveness and safety of other treatments, and a greater understanding of Long COVID’s pathophysiology could help design targeted interventions. In the absence of strong evidence, a holistic approach is recommended to support those living with Long COVID.

Reference url

Recent Posts

NICE Endorses Obecabtagene Autoleucel Therapy for Adult Relapsed B-Cell Leukaemia

By João L. Carapinha

November 25, 2025

NICE Backs Obecabtagene Autoleucel The National Institute for Health and Care Excellence (NICE) recommended obecabtagene autoleucel therapy, a UK-developed chimeric antigen receptor (CAR) T-cell trea...
Accelerating Access to Latin America Innovative Therapies Through Collaboration and Innovation
Accelerating Access to Latin America Innovative Therapies In this update we outline a strategic vision for transforming Latin America's healthcare systems through innovation, collaboration, and equitable access, with a stron...
Rethinking HEOR Market Access Integration: A Call for Early Engagement Before Phase 3

By João L. Carapinha

November 24, 2025

Early HEOR Market Access Integration In this brief interview on ISPOR, Indranil Bagchi asserts that HEOR market access integration must occur earlier in drug development—ideally before Ph...